Ehinger Johannes K, Morota Saori, Hansson Magnus J, Paul Gesine, Elmér Eskil
Mitochondrial Medicine Department of Clinical Sciences Lund University Lund Sweden.
Department of Otorhinolaryngology, Head and Neck Surgery Skåne University Hospital Lund Sweden.
Mov Disord Clin Pract. 2016 Feb 11;3(5):472-482. doi: 10.1002/mdc3.12308. eCollection 2016 Sep-Oct.
Patients with Huntington's disease display symptoms from both the central nervous system and peripheral tissues. Mitochondrial dysfunction has been implicated as part of the pathogenesis of the disease and has been reported in brain tissue and extracerebral tissues, such as muscle and blood cells, but the results are inconsistent. Therefore, the authors performed a refined evaluation of mitochondrial function in 2 types of peripheral blood cells from 14 patients with Huntington's disease and 21 control subjects. Several hypotheses were predefined, including impaired mitochondrial complex II function (primary), complex I function (secondary), and maximum oxidative phosphorylation capacity (secondary) in patient cells.
High-resolution respirometry was applied to viable platelets and mononuclear cells. Data were normalized to cell counts, citrate synthase activity, and mitochondrial DNA copy numbers.
Normalized to citrate synthase activity, platelets from patients with Huntington's disease displayed respiratory dysfunction linked to complex I, complex II, and lower maximum oxidative phosphorylation capacity. No difference was seen in mononuclear cells or when platelet data were normalized to cell counts or mitochondrial DNA. The ratio of complex I respiration through maximum oxidative phosphorylation was significantly decreased in patients compared with controls. The corresponding ratio for complex II was unaffected.
The data indicate decreased function of mitochondrial complex I in peripheral blood cells from patients with Huntington's disease, although this could not be uniformly confirmed. The results do not confirm a systemic complex II dysfunction and do not currently support the use of mitochondrial function in blood cells as a biomarker for the disease.
亨廷顿舞蹈症患者会出现中枢神经系统和外周组织的症状。线粒体功能障碍被认为是该疾病发病机制的一部分,并且在脑组织以及肌肉和血细胞等脑外组织中均有报道,但结果并不一致。因此,作者对14例亨廷顿舞蹈症患者和21名对照者的两种外周血细胞中的线粒体功能进行了精细评估。预先设定了几个假设,包括患者细胞中线粒体复合物II功能受损(主要)、复合物I功能受损(次要)以及最大氧化磷酸化能力受损(次要)。
对存活的血小板和单核细胞应用高分辨率呼吸测定法。数据根据细胞计数、柠檬酸合酶活性和线粒体DNA拷贝数进行标准化。
以柠檬酸合酶活性进行标准化后,亨廷顿舞蹈症患者的血小板显示出与复合物I、复合物II相关的呼吸功能障碍以及较低的最大氧化磷酸化能力。单核细胞中未观察到差异,血小板数据根据细胞计数或线粒体DNA进行标准化时也未观察到差异。与对照组相比,患者中通过最大氧化磷酸化的复合物I呼吸比率显著降低。复合物II的相应比率未受影响。
数据表明亨廷顿舞蹈症患者外周血细胞中线粒体复合物I功能下降,尽管这一点未能得到一致证实。结果未证实存在全身性复合物II功能障碍,目前也不支持将血细胞中的线粒体功能用作该疾病的生物标志物。